Concord Drugs Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 538965
₹74.53
▼ -3.73 (-4.77%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
41/100
Moderate
Valuation
60/100
Fairly Valued
Momentum
49/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹98 Cr
PE (TTM)
44.6
Industry median 36.1 (152 companies)
Price to Book
2.0
PEG (TTM)
0.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
98.3
Free Cash Flow
₹-8 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
663.64%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
6.73%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
162.92%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
107.22%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
56.07%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.53
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.28
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
3.05
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.45%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
9.07%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
4.39%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-8.79%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
5.43%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-13.03%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.28)
  • No Return on equity is 15% or more (-13.0%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 2 met
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-4.8%
Low 74.0000 · High 80.0000
1W return
-5.8%
Low 74.0000 · High 81.9800
1M return
-7.6%
Low 73.2000 · High 83.8900
52W return
98.3%
Low 70.0000 · High 84.9000
Lifetime High ₹88.0500 (April 16, 2015)
Lifetime Low ₹12.2900 (March 25, 2020)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish3
5D
76.7
10D
77.1
20D
76.7
50D
69.1
100D
59.6
200D
47.0

Delivery and volume

Day avg. delivery
63.3%
Week avg. delivery
76.1%
Month avg. delivery
73.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

76.18
Pivot
First resistance78.35
Second resistance82.18
Third resistance84.35
First support72.35
Second support70.18
Third support66.35
Day RSI48.4
Day MFI23.5
Day MACD1.66
Day MACD signal2.72

Beta

1M1.33
3M1.42
1Y1.42
3Y0.88

Price change analysis

↓ -7.6%
Over 1 Month
LowHigh
73.2083.89
↑ 98.3%
Over 3 Months
LowHigh
70.0084.90
↑ 98.3%
Over 6 Months
LowHigh
70.0084.90
↑ 98.3%
Over 1 Year
LowHigh
70.0084.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 44.6 (own history: 22.5–103.3)
Buy Zone
Revenue (June 30, 2026)
₹21 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.8400

Ranks #141 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter45.08%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings decreased from 54.39% to 45.08% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
4 Jul 2025 PRADEEP KUMAR JAIN Bulk Sell 69,944 54.4800 BSE
3 Jul 2025 GANGA DEVI LOYA Bulk Sell 11,555 53.9000 BSE
3 Jul 2025 GANGA DEVI LOYA Bulk Buy 51,655 53.2500 BSE
3 Jul 2025 PRADEEP KUMAR JAIN Bulk Sell 149,164 53.2100 BSE
30 Jun 2025 GANGA DEVI LOYA Bulk Buy 51,571 38.6600 BSE
15 Jan 2024 LAKSHMI PRASANNA PALLETI Bulk Sell 51,994 44.6300 BSE
29 Dec 2023 MATALIA STOCK BROKING PRIVATE LIMITED Bulk Buy 59,398 58.3600 BSE
29 Dec 2023 MATALIA STOCK BROKING PRIVATE LIMITED Bulk Sell 59,398 57.7100 BSE
28 Dec 2023 LAKHUBHA SOLANKI Bulk Sell 51,361 51.4600 BSE
28 Dec 2023 LAKHUBHA SOLANKI Bulk Buy 51,361 48.1000 BSE

All bulk and block deals →

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Concord Drugs Ltd - 538965 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Concord Drugs Ltd - 538965 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 Insider Trading / SAST Concord Drugs Ltd - 538965 - Closure of Trading Window
9 Sep 2026 Company Update Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.28)
  • Healthy liquidity (Current Ratio 2.53)
  • Strong revenue growth YoY (56.1%)

Weaknesses

  • Low Return on Equity (-13.0%)
  • Thin net profit margin (1.5%)

Opportunities

  • PEG below 1 (0.17) -- earnings growth outpacing its own valuation

Threats

  • PE above 35 (44.6) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Concord Drugs Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.